![](https://kalivir.com/wp-content/uploads/2024/01/2023-ovs-tile-cover-page.png)
Boston, MA
“VET3-TGI, a TGF-Beta Targeting Clinical Oncolytic Virus Developed from the VET Platform for Systemic Delivery”
SPEAKER : Steve Thorne, PhD
![](https://kalivir.com/wp-content/uploads/2024/01/2023-iovc-tile-cover-page.png)
Banff, AB, Canada
“Novel Oncolytic Viral Immunotherapy VET3-TGI displays enhanced systemic delivery and inhibits TGF β -signaling while augmenting Type-1 immune response in the tumor”
SPEAKER : Steve Thorne, PhD
![](https://kalivir.com/wp-content/uploads/2024/01/2023-aacr-tile-cover-page.png)
Orlando, FL
The oncolytic virus VET3-TGI both blocks TGF-beta signaling and activates type 2 IFN responses, resulting in potent therapeutic responses in multiple mouse models
SPEAKER : Ravikumar Muthuswamy, PhD
![](https://kalivir.com/wp-content/uploads/2024/01/2023-asgct-tile-cover-page.png)
Los Angeles, CA
“Novel Oncolytic therapy VET3-TGI restricts TGFβ1 and augments Type-1 immune response in TME, leading to superior therapeutic efficacy in multiple preclinical tumor models”
SPEAKER : Ravikumar Muthuswamy, PhD
![](https://kalivir.com/wp-content/uploads/2022/11/2022_SITC_Exhibitor_Prospectus_Image.png)
Boston, MA
A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models.
SPEAKER : Ravikumar Muthuswamy, PhD
![](https://kalivir.com/wp-content/uploads/2022/03/vaccine.jpg)
Washington | DC
Novel Vaccinia Enhanced Template (VET) Oncolytic Platform
SPEAKER : Steve Thorne, PhD
![](https://kalivir.com/wp-content/uploads/2022/03/tg.jpg)
Expression of a TGF-β Inhibitor from an Oncolytic Vaccinia Virus
SPEAKER : Steve Thorne, PhD
![](https://kalivir.com/wp-content/uploads/2021/11/Screen-Shot-2021-11-24-at-8.32.35-AM.png)
The VET Platform: Re-targeting Oncolytic Vaccinia Virus to Tumors through Expression of Chemokine Receptors
SPEAKER : Steve Thorne, PhD
![](https://kalivir.com/wp-content/uploads/2021/06/sum.jpg)
Boston | MA
The Design of Oncolytic Viral Therapies for Intravenous Delivery
SPEAKER : Steve Thorne, PhD
![](https://kalivir.com/wp-content/uploads/2021/04/Screen-Shot-2021-04-30-at-11.12.20-PM.png)
Oxford Global
A Dual Pipeline Strategy Bringing Potent Vaccinia-Based Oncolytic Immunotherapies to the Clinic
SPEAKER : Steve Thorne, PhD
![](https://kalivir.com/wp-content/uploads/2021/05/KALIVIRWeb-1.png)